(NewsNation) — The popular weight loss drugs Ozempic and Wegovy may reduce the rates of severe COVID-19 reactions, including death, a new study found. Published in the Journal of the American College of Cardiology, the trial examined 17,604 people over more than three years. It found that, while taking semaglutide once a weekly did not reduce rates of COVID-19 overall, it led to fewer "COVID-19 related adverse events." Placebo-takers recorded a 3.1% occurrence, while those on the weight loss drugs noted 2.6%. Compounded weight loss drugs: What are people saying about them? Participants were: 45 years or older Overweight or had obesity Diagnosed with card
Hence then, the article about ozempic cuts risk of severe covid in people with obesity was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Ozempic cuts risk of severe COVID in people with obesity )